Commonwealth Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$227K Buy
+457
New +$203K 0.03% 265
2026
Q1
Sell
-485
Closed -$220K 290
2025
Q4
$220K Buy
+485
New +$209K 0.04% 210
2025
Q3
Sell
-462
Closed -$206K 239
2025
Q2
$206K Sell
462
-3
-0.6% -$1.38K 0.04% 202
2025
Q1
$226K Buy
+465
New +$217K 0.05% 179
2024
Q4
Sell
-437
Closed -$205K 200
2024
Q3
$205K Buy
+437
New +$210K 0.04% 186

Other funds holding VRTX

Commonwealth Financial Services's VRTX Position: Q2 2026 in Review

Commonwealth Financial Services opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 457 shares worth $227K. The stake represents 0.03% of the portfolio and ranks #265 among its holdings. This is a return to the name: Commonwealth Financial Services previously reported a position in VRTX as recently as Q4 2025.

Commonwealth Financial Services first reported a position in VRTX in Q3 2024 and has held it in 5 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Commonwealth Financial Services held 457 shares of Vertex Pharmaceuticals worth $227K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Commonwealth Financial Services position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.03% of Commonwealth Financial Services's portfolio in Q2 2026, its #265 holding.
  • Commonwealth Financial Services first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Commonwealth Financial Services's 13F filing for Q2 2026, filed 15 Jul 2026.